Informação sobre produto
- (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)piperidino]-4-oxo-3-quinolinecarboxylic acid
- 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-8-Methoxy-7-[3-(Methylamino)-1-Piperidino]-4-Oxo-3-Quinoline Carboxylic Acid
- 1-Cyclopropyl-6-Fluoro-8-Methoxy-7-[3-(Methylamino)Piperidin-1-Yl]-4-Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid
- 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo-3-quinolinecarboxylic acid
- 1-Cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
- 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3 ?carboxylic acid
- 1-cyclopropyl-6-fluoro-8-methoxy-7-[(3R)-3-(methylamino)piperidin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo-
- Balorain
- Q 35 (pharmaceutical)
- Ver mais sinónimos
Balofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, which is an enzyme that maintains the integrity of bacterial DNA. It binds to bacterial 16S ribosomal RNA and inhibits protein synthesis, leading to cell death by inhibiting the production of proteins vital for cell division. Balofloxacin has been shown to be effective against resistant strains of bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Balofloxacin has also been shown to have low potency in animal models and humans. The long-term toxicity of balofloxacin has been studied in rats and mice using a model system. Balofloxacin showed no chronic toxicity in these studies at doses up to 1g/kg/day for 26 weeks.
Propriedades químicas
Consulta técnica sobre: 3D-AB39133 Balofloxacin
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.